Venous thromboembolic disease in congestive heart failure

Congestive Heart Failure

Volumn 16, Issue 4, 2010, Pages 164-169

  Dean, Steven M ^a   Abraham, William ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO;

ARTICLE; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; HEART LEFT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FAILURE; HOSPITALIZATION; HUMAN; PATHOPHYSIOLOGY; PHLEBOGRAPHY; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CONFIDENCE INTERVALS; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; HEART FAILURE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; RETROSPECTIVE STUDIES; RISK; RISK FACTORS; STROKE VOLUME; UNITED STATES; VENOUS THROMBOEMBOLISM; VENTRICULAR FUNCTION, LEFT;

EID: 77955136810     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2010.00148.x     Document Type: Article

References (46)

1. Heit JA, Cohen AT, Anderson FA. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood 2005, 106. ASH Annual Meeting Abstracts, Abstract 910
2. Geerts WH, Pineo GF, Heit JA. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 3(suppl):338S-400S.
3. Clagett GP, Anderson FA, Heit J. Prevention of venous thromboembolism. Chest 1995, 108(4 suppl):312S-334S.
4. Ginsberg JS, Hirsh J, Julian J. Prevention and treatment of postphlebitic syndrome: results of a 3-part study. Arch Intern Med. 2001, 161:2105-2109.
5. Kahn SR, Kearon C, Julian JA. Predictors of the post-thrombotic syndrome during long-term treatment of proximal deep vein thrombosis. J Thromb Haemost 2005, 3:718-723.
6. Prandoni P, Lensing AW, Cogo A. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996, 125:1-7.
7. Brandjes DP, Buller HR, Heijboer H. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997, 349:759-762.
8. Willey VJ, Bullano MF, Hauch O. Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. Clin Ther. 2004, 26:1149-1159.
9. Bullano MF, Willey V, Hauch O. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization. J Manag Care Pharm 2005, 11:663-673.
10. MacDougall DA, Feliu AL, Boccuzzi SJ. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Health Syst Pharm 2006, 63(20 suppl 6):S5-S15.
11. Heit JA, Silverstein MD, Mohr DN. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 1999, 159:445-453.
12. Piovella F, D'Armini AM, Barone M. Chronic thromboembolic pulmonary hypertension. Semin Thromb Hemost 2006, 32:848-855.
13. Heit JA, O'Fallon WM, Peterson TM. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002, 162:1245-1248.
14. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000, 160:3415-3420.
15. Howell MD, Geraci JM, Knowlton AA. Congestive heart failure and outpatient risk of venous thromboembolism: a retrospective, case-control study. J Clin Epidemiol 2001, 54:810-816.
16. Harvey WP, Finch CA. Dicumarol prophylaxis of thromboembolic disease in congestive heart failure. N Engl J Med 1950, 242:208-211.
17. Beemath A, Stein PD, Skaf E. Risk of venous thromboembolism in patients hospitalized with heart failure. Am J Cardiol 2006, 98:793-795.
18. Alikhan R, Cohen AT, Combe S. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis 2003, 14:341-346.
19. Monreal M, Munoz-Torrero JF, Naraine VS. Pulmonary embolism in patients with chronic obstructive pulmonary disease or congestive heart failure. Am J Med 2006, 119:851-858.
20. Beemath A, Skaf E, Stein PD. Pulmonary embolism as a cause of death in adults who died with heart failure. Am J Cardiol 2006, 98:1073-1075.
21. Roberts WC, Siegel RJ, McManus BM. Idiopathic dilated cardiomyopathy: analysis of 152 necropsy patients. Am J Cardiol 1987, 60:1340-1355.
22. Gangireddy C, Rectenwald JR, Upchurch GR. Risk factors and clinical impact of postoperative symptomatic venous thromboembolism. J Vasc Surg 2007, 45:335-341.
23. Dries DL, Rosenberg YD, Waclawiw MA. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol 1997, 29:1074-1080.
24. Darze ES, Latado AL, Guimaraes AG. Incidence and clinical predictors of pulmonary embolism in severe heart failure patients admitted to a coronary care unit. Chest 2005, 128:2576-2580.
25. Gibbs CR, Blann AD, Watson RD. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation 2001, 103:1746-1751.
26. Chong AY, Lip GY. Viewpoint: the prothrombotic state in heart failure: a maladaptive inflammatory response? Eur J Heart Fail 2007, 9:124-128.
27. Chung I, Choudhury A, Lip GY. Platelet activation in acute, decompensated congestive heart failure. Thromb Res 2007, 120:709-713.
28. Marucci R, Gori AM, Giannotti F. Markers of hypercoagulability and inflammation predict mortality in patients with heart failure. J Thromb Haemost. 2006, 4:1017-1022.
29. Samama MM, Cohen AT, Darmon JY. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999, 341:793-800.
30. Leizorovicz A, Cohen AT, Turpie AG. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004, 110:874-879.
31. Cohen AT, Davidson BL, Gallus AS. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomized placebo controlled trial. Br Med J. 2006, 332:325-329.
32. Kleber FX, Witt C, Vogel G. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 2003, 145:614-621.
33. Heit JA, Silverstein MD, Mohr DN. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000, 160:809-815.
34. Geerts WH, Bergqvist D, Pineo GF. Prevention of Venous Thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133(6 suppl):381S-453S.
35. International Consensus Statement (guidelines according to scientific evidence). Int Angiol 2006, 25:101-161.
36. Tapson VF, Decousus H, Pini M. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest 2007, 132:936-945.
37. Amin A, Stemkoswski S, Lin J. Thromboprophylaxis rates in US medical centers: success or failure? J Thromb Haemost 2007, 5:1610-1616.
38. Cohen AT, Tapson VF, Bergmann JF. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008, 371:387-394.
39. Goldhaber SZ, Tapson VF. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol 2004, 93:259-262.
40. Hunt SA. ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. J Am Coll Cardiol 2001, 38:2101-2113.
41. Adams KF, Lindenfeld J, Arnold JMO. Executive Summary: HFSA 2006. Comprehensive Heart Failure Practice Guidelines. J Card Fail 2006, 12:10-38.
42. Nieminem MS, Bohm M, Cowie MR. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. Eur Heart J 2005, 26:384-416.
43. Vaitkus PT, Leizovovicz A, Cohen AT. Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. Thromb Haemost 2005, 93:7609.
44. Goldhaber SZ, Savage DD, Garrison RJ. Risk factors for pulmonary embolism. The Framingham Study. Am J Med 1983, 74:1023-1028.
45. Cohen AT, Alikhan R, Arcelus JI. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost 2005, 94:750-759.
46. Hull RD, Schellong SM, Tapson VF. Extended-duration venous thromboembolism (VTE) prophylaxis in acutely ill medical patients with recent reduced mobility: the EXCLAIM study. J Thromb Haemost 2007, 5(suppl 2):OS001.